(19)
(11) EP 3 230 319 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.10.2022 Bulletin 2022/41

(45) Mention of the grant of the patent:
07.09.2022 Bulletin 2022/36

(21) Application number: 15808464.0

(22) Date of filing: 02.12.2015
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/00(2006.01)
 A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2818; A61K 2039/545; C07K 2317/24; C07K 2317/94; C07K 16/2878; A61K 2039/53; C07K 2317/55; C07K 2317/74; A61K 39/3955; C07K 2317/76; C07K 2317/33; C07K 2317/92; A61K 2039/505; A61K 2039/507; A61P 1/02; A61P 1/04; A61P 1/16; A61P 1/18; A61P 11/00; A61P 13/08; A61P 13/10; A61P 13/12; A61P 15/00; A61P 17/00; A61P 19/00; A61P 21/00; A61P 25/00; A61P 35/00; A61P 35/02; A61P 43/00; A61P 5/00; A61K 39/0011
 
C-Sets:
A61K 39/3955, A61K 2300/00;
(86) International application number:
PCT/IB2015/059268
(87) International publication number:
WO 2016/092419 (16.06.2016 Gazette 2016/24)

(54)

ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF

ANTI-PD-1-ANTIKÖRPER UND VERFAHREN ZU DEREN VERWENDUNG

ANTICORPS DIRIGÉS CONTRE LA PROTÉINE DE MORT PROGRAMMÉE 1 (PD-1)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.12.2014 US 201462089658 P
16.10.2015 US 201562242750 P
06.11.2015 US 201562251973 P

(43) Date of publication of application:
18.10.2017 Bulletin 2017/42

(60) Divisional application:
22194128.9

(73) Proprietor: Rinat Neuroscience Corp.
New York, NY 10017 (US)

(72) Inventors:
  • ABDICHE, Yasmina Noubia
    South San Francisco, California 94080 (US)
  • CHO, Helen Kim
    San Diego, California 92130 (US)
  • HO, Weihsien
    Belmont, California 94002 (US)
  • JOOSS, Karin Ute
    San Diego, California 92106 (US)
  • RAJPAL, Arvind
    San Francisco, California 94127 (US)
  • YOUSSEF, Sawsan
    Menlo Park, California 94025 (US)

(74) Representative: Pfizer 
European Patent Department 23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14
75668 Paris Cedex 14 (FR)


(56) References cited: : 
WO-A1-2014/159562
 WO-A2-2014/179664
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).